Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04754945 · ClinicalTrials.gov registry record · Phase 1
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
A Phase 1 study of AL Amyloidosis, sponsored by Emory University.
- Active
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 6
- Study locations
NCT04754945 is a Phase 1 study of AL Amyloidosis that is active but no longer recruiting, run by Emory University. The registered enrollment target is 11 participants, below the 424-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04754945, a Phase 1 study of AL Amyloidosis, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Bortezomib
- BIOLOGICAL Isatuximab
Study Locations (6)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Emory University Hospital Midtown - Atlanta
California
- University of California - Orange
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Columbia University - New York
Texas
- UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2026-07-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04754945
The ClinicalTrials.gov registry entry for NCT04754945 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 424-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (97% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04754945 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Georgia, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT04754945 about?
NCT04754945 is a clinical study titled "Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis". This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT04754945?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2021-04-28. Estimated completion is 2026-07-24.
What conditions does trial NCT04754945 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT04754945?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Bortezomib (DRUG), Isatuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04754945?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04754945 being conducted?
This trial has 6 study locations across California, Georgia, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
RECRUITING · Phase 1
-
Radioimmunoimaging of AL Amyloidosis
COMPLETED · Phase 1
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.